4 Ways to Ensure the Success of Your COVID-19 Trial

Dr. Carol Olson, M.D., Ph.D. serves as the vice president and infectious diseases therapeutic area head in global product development for PPD. She has been with PPD for seven years with five years of experience in pharma and CROs. In this role, she is responsible for supporting pharmaceutical development consulting services focused on antibacterial product development strategies. Dr. Olson is an infectious diseases physician with extensive pharmaceutical development experience. Her primary area of expertise includes strategic planning and execution of clinical programs from drug candidate status through registration, launch and post-approval.

Dr. Heather Myler currently serves as the director of R&D, immunochemistry at PPD (NC, USA), leading a group of scientists responsible for bioanalytical and biomarker method development, validation and automation supporting gene and cell therapies, biosimilars and novel biologics. Dr. Myler has 18 years bioanalytical experience and has been with PPD Laboratories for 3 years.

Katie Matys has over 15 years of experience in the pharmaceutical industry. In 2002, she started with Centocor in the core molecular and flow cytometry laboratories and transitioned to Merck in 2005, where she was part of the vaccine sciences department, developing and validating ligand binding methods in support of Gardasil®. In 2009, she joined PPD and has held a variety of roles and titles, with the most recent as director of the biomarker group.